Skip to main content

Table 2 Clinical characteristics and pathologic data of 20 patients enrolled in the study

From: EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches

Clinical characteristics Number of patients (%)
Gender  
 Male 15 (75)
 Female 5 (25)
WBC  
 ≤20.000/mm3 6 (30)
 >20.000/mm3 14 (70)
FAB phenotype  
 L1 4 (20)
 L2 16 (80)
Disease Status  
 Relapsed 9 (45)
 No relapsed 11 (55)
Risk  
 Standard 3 (15)
 High 17 (85)
PDN  
 GR 7 (35)
 PR 13 (65)
  1. WBC White Blood Cell, PDN Prednisone, GR Good Responders, PR Poor Responders